Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Information from the National Library of Medicine NIH NLM ABRV BLK 4

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05682170

Contacts

Layout table for location contacts
Contact: K-Group Alpha, Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.(212) 433-3791info@zenopharma.com

Locations

Layout table for location information
United States, Alabama
Investigative Site 0108Not yet **RECRUITING NOW**
Birmingham, Alabama, United States, 35233
United States, California
Site 0266Not yet **RECRUITING NOW**
San Francisco, California, United States, 94110
United States, New York
Site 0105**RECRUITING NOW**
New York, New York, United States, 10065

Sponsors and Collaborators

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Investigators

Layout table for investigator information
Study Director:K-Group Alpha, Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.K-Group Alpha

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 14, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments